Skip to content

Anthony N. Gerber, MD, PhD

Make an Appointment
Anthony N. Gerber

Dr. Anthony Gerber is a fellowship-trained pulmonologist and researcher. He treats all lung diseases, including asthma, COPD and chronic cough.



Special Interests


Research Interests

The glucocorticoid receptor is one of the most important therapeutic targets for the treatment of inflammatory disorders of the lung such as asthma. My laboratory investigates two aspects of glucocorticoid receptor signaling. First, we are studying the basic molecular mechanisms whereby glucocorticoids repress the expression of inflammatory genes in the airway. Second, we are investigating how various non-inflammatory genes that are regulated by glucocorticoids alter lung function. By defining new mechanisms of glucocorticoid action we ultimately seek to discover new targets for asthma therapeutics.

Education


Education

1990
Massachusetts Institute of Technology, BS, Mathematics
1998
University of Washington, MD, PhD

Residency

1998 - 2000
University of California, San Francisco, Internal Medicine

Fellowship

2001 - 2004
University of California, San Francisco, Pulmonary and Critical Care

Board Certification


Internal Medicine
Pulmonary Disease

Professional Memberships


American Thoracic Society
American Physiological Society
American Lung Association of Colorado

Publications


α1-Antitrypsin Binds to the Glucocorticoid Receptor with Anti-Inflammatory and Antimycobacterial Significance in Macrophages. Bai X, Bai A, Tomasicchio M, Hagman JR, Buckle AM, Gupta A, Kadiyala V, Bevers S, Serban KA, Kim K, Feng Z, Spendier K, Hagen G, Fornis L, Griffith DE, Dzieciatkowska M, Sandhaus RA, Gerber AN, Chan ED. J Immunol. 2022 Nov 1;209(9):1746-1759. doi: 10.4049/jimmunol.2200227. Epub 2022 Sep 26.PMID: 36162872 

The Impact of Escape Room Gamification Using a Teleconferencing Platform on Pharmacy Student Learning. Gerber A, Fischetti B.Med Sci Educ. 2022 Sep 19;32(5):1159-1164. doi: 10.1007/s40670-022-01641-7. eCollection 2022 Oct. PMID: 36160293 Free PMC article.

Integrated genomics approaches identify transcriptional mediators and epigenetic responses to Afghan desert particulate matter in small airway epithelial cells. Gupta A, Sasse SK, Berman R, Gruca MA, Dowell RD, Chu HW, Downey GP, Gerber AN. Physiol Genomics. 2022 Oct 1;54(10):389-401. doi: 10.1152/physiolgenomics.00063.2022. Epub 2022 Sep 5.PMID: 36062885

Sasse SK, Gerber AN. Feed-forward transcriptional programming by nuclear receptors: regulatory principles and therapeutic implications. Pharmacol Ther. 2015 Jan;145:85-91. Epub 2014 Feb 5.
 
Sasse SK, Zuo Z, Kadiyala V, Zhang L, Pufall MA, Jain MK, Phang TL, Stormo GD, Gerber AN. Response Element Composition Governs orrelations between Binding Site Affinity and Transcription in Glucocorticoid Receptor Feed-forward Loops. J Biol Chem. 2015 Aug 7;290(32):19756-69. Epub 2015 Jun 18.
 
Gerber AN. Glucocorticoids and the Lung. Adv Exp Med Biol. 2015;872:279-98.
 
Morrison-Nozik A, Anand P, Zhu H, Duan Q, Sabeh M, Prosdocimo DA, Lemieux ME, Nordsborg N, Russell AP, MacRae CA, Gerber AN, Jain MK, Haldar SM. Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program. Proc Natl Acad Sci USA. 2015 Dec 8;112(49):E6780-9. Epub 2105 Nov 23.
  
Kadiyala V, Sasse SK, Altonsy MO, Berman R, Chu HW, Phang TL, Gerber AN. Cistrome-based Cooperation Between Airway Epithelial Glucocorticoid Receptor and NF-kB Orchestrates Anti-inflammatory Effects. J Biol Chem. 2016 Apr 13.

Hospital Affiliations


  • Rose Medical Center

Academic Affiliations


Professor of Medicine, University of Colorado Denver
Associate Professor of Medicine, University of Colorado Denver
Graduate Faculty, Department of Pharmacology, University of Colorado Denver

Website Information


Gerber Lab

Conflicts of Interest


National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.